Zürcher Nachrichten - Formerra and Evonik Expand Distribution Partnership for Healthcare Grades

EUR -
AED 4.324861
AFN 77.137568
ALL 96.460586
AMD 445.157996
ANG 2.108059
AOA 1079.890395
ARS 1698.479772
AUD 1.705135
AWG 2.119742
AZN 2.005099
BAM 1.953468
BBD 2.372568
BDT 144.068027
BGN 1.977684
BHD 0.44393
BIF 3485.797439
BMD 1.177634
BND 1.500309
BOB 8.139319
BRL 6.207315
BSD 1.177994
BTN 106.457922
BWP 15.59545
BYN 3.374272
BYR 23081.63169
BZD 2.369072
CAD 1.615302
CDF 2626.124609
CHF 0.915687
CLF 0.025849
CLP 1020.667444
CNY 8.170485
CNH 8.172258
COP 4358.247788
CRC 584.002882
CUC 1.177634
CUP 31.207308
CVE 110.491552
CZK 24.264035
DJF 209.288967
DKK 7.467267
DOP 74.185127
DZD 153.163139
EGP 55.190887
ERN 17.664514
ETB 182.70979
FJD 2.610695
FKP 0.862245
GBP 0.871208
GEL 3.17368
GGP 0.862245
GHS 12.924537
GIP 0.862245
GMD 85.967637
GNF 10316.667086
GTQ 9.035215
GYD 246.44582
HKD 9.200904
HNL 31.1543
HRK 7.533683
HTG 154.535533
HUF 380.092914
IDR 19886.651034
ILS 3.674154
IMP 0.862245
INR 106.358098
IQD 1543.289711
IRR 49607.843805
ISK 144.719149
JEP 0.862245
JMD 184.240074
JOD 0.834931
JPY 184.521195
KES 151.915275
KGS 102.984555
KHR 4749.399502
KMF 493.428622
KPW 1059.906177
KRW 1734.219654
KWD 0.362052
KYD 0.981674
KZT 580.976494
LAK 25319.137213
LBP 100746.611673
LKR 364.534858
LRD 219.21631
LSL 19.198006
LTL 3.477248
LVL 0.712339
LYD 7.448551
MAD 10.816509
MDL 20.019188
MGA 5228.695746
MKD 61.635279
MMK 2472.776671
MNT 4203.161543
MOP 9.479667
MRU 46.929186
MUR 54.229883
MVR 18.194093
MWK 2045.550994
MXN 20.665359
MYR 4.653189
MZN 75.073694
NAD 19.198227
NGN 1609.951335
NIO 43.160216
NOK 11.561663
NPR 170.332676
NZD 1.984738
OMR 0.452809
PAB 1.178004
PEN 3.965684
PGK 5.02378
PHP 69.262559
PKR 329.377424
PLN 4.224692
PYG 7778.714627
QAR 4.288178
RON 5.091741
RSD 117.381906
RUB 90.387639
RWF 1711.102594
SAR 4.416335
SBD 9.489552
SCR 17.256641
SDG 708.355379
SEK 10.676043
SGD 1.50259
SHP 0.883531
SLE 28.793162
SLL 24694.40096
SOS 673.019067
SRD 44.59678
STD 24374.651753
STN 24.789201
SVC 10.306697
SYP 13024.134407
SZL 19.18933
THB 37.507879
TJS 11.025639
TMT 4.127608
TND 3.353317
TOP 2.83546
TRY 51.362169
TTD 7.976479
TWD 37.288494
TZS 3044.18453
UAH 50.831223
UGX 4204.980557
USD 1.177634
UYU 45.45574
UZS 14455.460887
VES 445.128237
VND 30565.497475
VUV 140.948305
WST 3.210637
XAF 655.205488
XAG 0.018051
XAU 0.000251
XCD 3.182616
XCG 2.122975
XDR 0.813864
XOF 652.918525
XPF 119.331742
YER 280.72331
ZAR 19.233223
ZMK 10600.118823
ZMW 21.881067
ZWL 379.197754
  • SCS

    0.0200

    16.14

    +0.12%

  • CMSD

    0.0200

    23.89

    +0.08%

  • JRI

    -0.1500

    13

    -1.15%

  • BCC

    -1.0700

    89.16

    -1.2%

  • CMSC

    0.0300

    23.55

    +0.13%

  • NGG

    -0.9000

    86.89

    -1.04%

  • BTI

    0.3300

    61.96

    +0.53%

  • RBGPF

    0.1000

    82.5

    +0.12%

  • GSK

    1.9400

    59.17

    +3.28%

  • RIO

    -5.3600

    91.12

    -5.88%

  • BCE

    -0.7700

    25.57

    -3.01%

  • BP

    -1.0300

    38.17

    -2.7%

  • AZN

    -0.2900

    187.16

    -0.15%

  • RYCEF

    -0.0600

    16.62

    -0.36%

  • VOD

    -1.0900

    14.62

    -7.46%

  • RELX

    0.3100

    30.09

    +1.03%

Formerra and Evonik Expand Distribution Partnership for Healthcare Grades
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades

Formerra and Evonik Expand Distribution Partnership for Healthcare Grades

Agreement Expands Access to Evonik's CARE Brand Medical Grades in the U.S. and Canada

Text size:

ROMEOVILLE, ILLINOIS / ACCESS Newswire / February 2, 2026 / Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik's CARE brand healthcare grades into Formerra's medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications.

This expansion kicks off at MD&M West 2026 this week, and underscores both companies' commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies' two-year partnership, which introduced Evonik's VESTAMID® and TROGAMID® families to Formerra's engineered materials lineup.

With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgical instrument parts, medical device housings, components that see short-term body contact (

Key medical grade materials include:

  • VESTAMID® Care ML PA12

  • VESTAMID® Care ME PEBA elastomer

  • TROGAMID® Care MX microcrystalline PA

"Our healthcare customers rely on stable supply, world-class regulatory support, and materials that perform under demanding conditions," said Steve Harmon, Director, Key Accounts, Formerra. "Evonik's healthcare grades bring the combination of durability, processing consistency, and documentation support that medical manufacturers require. This expansion lets us strengthen the technical resources and materials pipeline available to teams developing next-generation devices."

"Formerra's ability to serve the whole supply chain in the medical space, from design companies to compounders to medical device OEMs, with technical rigor and exceptional logistics and with already-proven successful demonstration in the industrial space, made this expansion with CARE brand Polyamide 12 products a natural step," said Basker Lalgudi, Business Manager, Global Medical Devices, Evonik. "Their healthcare expertise and focus help customers select and implement our materials with confidence across a range of critical applications."

By adding Evonik's healthcare CARE brand materials, Formerra will offer customers a proven set of polyamide solutions that support regulatory pathways, design requirements, and long-term reliability. Formerra's team will provide material selection guidance, processing support, and regional supply chain readiness to help OEMs and molders accelerate development cycles.

Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, Feb. 3-5, 2026.

Key Details:

  • Formerra will distribute Evonik's CARE brand healthcare grades across the U.S. and Canada.

  • Materials include healthcare grades within the VESTAMID® L, VESTAMID® E, and TROGAMID® CX families, plus designated sustainable options.

  • The agreement strengthens Formerra's medical portfolio and expands its support for fluid management, diagnostics, wearables, and device housings.

  • Formerra will provide application guidance, regulatory documentation support, and supply chain continuity for medical customers.

About Formerra

Formerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways, driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.

About Evonik

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day. To learn more, visit www.evonik.com.

Media Contact
Jackie Morris
Marketing Communications Manager, Formerra
[email protected]
+1 630-972-3144

SOURCE: Formerra



View the original press release on ACCESS Newswire

P.E.Steiner--NZN